Literature DB >> 32469899

An investigation of the correlation between the S-glutathionylated GAPDH levels in blood and Alzheimer's disease progression.

Chen Wei Tsai1, Chia Fan Tsai2, Kuan Hung Lin3, Wei Jung Chen1, Muh Shi Lin1,4,5,6, Cho Chen Hsieh7, Chai Ching Lin1.   

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by two aggregates, namely, amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs) of hyperphosphorylated tau protein (tau-p), which are released into the blood in a very small amount and cannot be easily detected. An increasing number of recent studies have suggested that S-glutathionylated glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is highly correlated with Aβ in patients with AD and that S-glutathionylated GAPDH plays a role as a proapoptotic factor in AD. We found that S-glutathionylated GAPDH is abundant in the blood of AD patients, which is unusual because S-glutathionylated GAPDH cannot exist in the blood under normal conditions. The aim of this study was to further explore the correlation between the S-glutathionylated GAPDH levels in blood plasma and AD progression. As controls, we recruited 191 people without AD, which included 111 healthy individuals and 37 patients with depression and insomnia, in the psychosomatic clinic. Moreover, 47 patients with AD (aged 40-89 years) were recruited at the neurology clinic. The blood S-glutathionylated GAPDH levels in the AD patients were significantly (p < 0.001) higher (752.7 ± 301.7 ng/dL) than those in the controls (59.92 ± 122.4 ng/dL), irrespective of gender and age. For AD diagnosis, the criterion blood S-glutathionylated GAPDH level > 251.62 ng/dL exhibited 95.74% sensitivity and 92.67% specificity. In fact, the individuals aged 70-89 years, namely, 37 patients from the psychosomatic clinic and 42 healthy individuals, showed significant blood S-glutathionylated GAPDH levels (230.5 ± 79.3 and 8.05 ± 20.51 ng/dL, respectively). This finding might indicate neurodegenerative AD progression in psychosomatic patients and suggests that the degree of neuronal apoptosis during AD progression might be sensitively evaluated based on the level of S-glutathionylated GAPDH in blood.

Entities:  

Year:  2020        PMID: 32469899     DOI: 10.1371/journal.pone.0233289

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  4 in total

1.  TRPM2 Channel Inhibition Attenuates Amyloid β42-Induced Apoptosis and Oxidative Stress in the Hippocampus of Mice.

Authors:  Ramazan Çınar; Mustafa Nazıroğlu
Journal:  Cell Mol Neurobiol       Date:  2022-07-15       Impact factor: 4.231

2.  Mechanism of GAPDH Redox Signaling by H2O2 Activation of a Two-Cysteine Switch.

Authors:  Paul A Hyslop; Michael O Chaney
Journal:  Int J Mol Sci       Date:  2022-04-21       Impact factor: 6.208

Review 3.  Metabolic Features of Brain Function with Relevance to Clinical Features of Alzheimer and Parkinson Diseases.

Authors:  David Allan Butterfield; Maria Favia; Iolanda Spera; Annalisa Campanella; Martina Lanza; Alessandra Castegna
Journal:  Molecules       Date:  2022-01-30       Impact factor: 4.411

Review 4.  Enzymes in the time of COVID-19: An overview about the effects in the human body, enzyme market, and perspectives for new drugs.

Authors:  Luana Xavier Soares Gomes Moura Fé; Eliane Pereira Cipolatti; Martina Costa Cerqueira Pinto; Suema Branco; Fábio César Sousa Nogueira; Gisela Maria Dellamora Ortiz; Anderson de Sá Pinheiro; Evelin Andrade Manoel
Journal:  Med Res Rev       Date:  2022-06-28       Impact factor: 12.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.